Application of salidroside in improving quality and fertilization of elderly female oocytes and embryonic development after fertilization

By using rhodiolisin to enhance mitochondrial autophagy of oocytes and adding rhodiolisin during in vitro maturation, the problem of low oocyte quality and fertilization rate in elderly women was solved, and the fertilization rate and embryonic development potential were significantly improved. , delays ovarian aging and provides an effective treatment plan with few side effects.

CN118924771APending Publication Date: 2024-11-12THE UNIVERSITY OF HONG KONG SHENZHEN HOSPITAL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411023947.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

No approved drugs in the prior art can effectively treat ovarian aging, resulting in a decrease in fertility in older women, especially the problem of reduced oocyte quality and fertilization rate.

Method used

Rhodiolain is used as a drug to enhance the mitochondrial autophagy of oocytes in older females, improve the quality and fertilization rate of oocytes, and add rhodiolain during in vitro maturation to improve the foaming of oocytes. rupture rate and polar body discharge rate, thereby improving oocyte mass and embryonic development in older females.

Benefits of technology

Rhodiolain significantly improves the fertilization rate, 2-cell embryo rate and embryo rate of oocytes in older females, delays ovarian aging, provides a treatment plan with fewer side effects, and improves the fertility of older females.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924771A_ABST
    Figure CN118924771A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, in particular to application of salidroside in improving the quality and fertilization of elderly female oocytes and embryonic development after fertilization. The innovation key of the invention lies in that a brand new treatment scene of the salidroside is found, and on the basis of the original curative effect of the salidroside, the salidroside is found to be capable of improving the quality of elderly female oocytes, increasing the fertilization rate and promoting early embryo development after fertilization, and has a certain effect on delaying ovarian aging.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of pharmaceutical technology, and in particular to application of salidroside in improving the quality of oocytes, fertilization and embryonic development after fertilization of advanced-age females. Background Art

[0002] Delayed childbearing has become an increasingly common phenomenon due to the increase in women's education level and labor force participation. Reproductive aging of women has become a major obstacle for them when faced with the choice between career and family. Women's fertility shows a downward trend after their early 30s, and this trend becomes more dramatic after the age of 35. Even though assisted reproductive technology (ART) can improve reproductive outcomes to a certain extent, the number of oocytes, pregnancy rate, and live birth rate after in vitro fertilization (IVF) treatment still decline with the increase of older maternal age. The main reason for the decline in fertility with increasing maternal age is ovarian aging, which is characterized by a decrease in the number of follicles and oocyte quality. Previous studies have shown that many supplements, including nicotinamide mononucleotide, spermidine, coenzyme Q10 (ubidecarenone), MitoQ (mitochondrial-directed coenzyme Q1), BGP-15, quercetin, and N-acetyl-L-cysteine, have positive effects on ovarian aging. However, there are currently no approved drugs for the treatment of ovarian aging. Therefore, there is an urgent need to find molecules or drugs with better efficacy and fewer side effects for ovarian aging. Summary of the invention

[0003] In view of the above-mentioned deficiencies in the prior art, the purpose of the present invention is to provide the use of salidroside in improving the quality of oocytes, fertilization and embryonic development after fertilization in elderly females, aiming to solve the problem that there are currently no approved drugs for the treatment of ovarian aging.

[0004] The technical solution of the present invention is as follows:

[0005] The first aspect of the present invention provides the use of salidroside in the preparation of a drug for improving the quality of oocytes, fertilization and embryonic development after fertilization in advanced females.

[0006] Optionally, the salidroside improves the quality of oocytes by enhancing mitochondrial autophagy in oocytes of advanced-age females.

[0007] Optionally, improving the fertilization and post-fertilization embryonic development of oocytes of advanced-age females includes increasing the fertilization rate, 2-cell rate and embryo rate of oocytes of advanced-age females after in vitro fertilization.

[0008] Optionally, the drug comprises salidroside at a concentration of 75 mg / kg, wherein the 75 mg / kg means that the amount of salidroside required per kilogram of body weight of the user is 75 mg.

[0009] Optionally, the elderly female is a woman over 30 years old.

[0010] Further optionally, the elderly female is a woman over 35 years old.

[0011] The second aspect of the present invention provides a drug for improving the quality of oocytes, fertilization and embryonic development after fertilization in advanced-age females, wherein the drug comprises an effective amount of salidroside.

[0012] Optionally, the drug comprises salidroside at a concentration of 75 mg / kg, wherein the 75 mg / kg means that the amount of salidroside required per kilogram of body weight of the user is 75 mg.

[0013] Optionally, the elderly female is a woman over 30 years old.

[0014] Further optionally, the elderly female is a woman over 35 years old.

[0015] The third aspect of the present invention provides the use of salidroside in the preparation of a drug for improving in vitro maturation of oocytes in advanced females.

[0016] Optionally, the addition of salidroside to the in vitro maturation medium of oocytes of advanced-age females can increase the germinal vesicle rupture rate and polar body extrusion rate of oocytes, so as to improve the in vitro maturation of oocytes of advanced-age females.

[0017] Optionally, the drug comprises salidroside at a concentration of 25 μM.

[0018] Optionally, the elderly female is a woman over 30 years old.

[0019] Further optionally, the elderly female is a woman over 35 years old.

[0020] Beneficial effects: The key innovation of the present invention lies in the discovery of a new treatment scenario for salidroside. Based on the original therapeutic effect of salidroside, it was found that salidroside can improve the quality of oocytes in older females, increase the fertilization rate, and promote early embryonic development after fertilization, and has a certain effect on delaying ovarian aging. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 This is the structural formula of salidroside.

[0022] Figure 2 This is a data chart showing that salidroside injection improves the fertility of 10-month-old female mice;

[0023] Figure 2In the figure, A is a timeline diagram of salidroside (Sal) administration, hormone initiation and subsequent analysis; where Sal: salidroside; hCG: human chorionic gonadotropin; PMSG: pregnant mare serum gonadotropin; MII: metaphase of the second meiotic division; GV: germinal vesicle stage; B is a schematic diagram of MII oocytes discharged after different treatments; C is a statistical diagram of the number of normal MII oocytes after different treatments, scale bar: 80μm; D is a diagram of embryonic development at different stages after in vitro fertilization of oocytes 14 days after intraperitoneal injection of salidroside in 10-month-old female mice, scale bar: 80μm; E is a fertilization rate statistics; F is a 2-cell embryo rate statistics; G is a blastocyst rate statistics. ns: p>0.05; *: p<0.05; **: p<0.01; ***: p<0.001. 2pn refers to fertilized eggs with two pronuclei, and the results represent the mean ± SEM of at least 3 independent experiments. Statistical analysis was performed using two-tailed unpaired t-test.

[0024] Figure 3 Salidroside improves in vitro maturation (IVM) of oocytes in aged mice;

[0025] Among them, A is a schematic diagram of salidroside treating aged mouse oocytes in vitro, Sal: salidroside; PMSG: pregnant mare serum gonadotropin; GV: germinal vesicle stage;

[0026] B is a representative image of germinal vesicle breakdown (GVBD) of oocytes from young (n=3, n is the number of mice), old+PBS (n=5), and old+Sal (n=5) mice 4 hours after IVM. Scale bar: 160 μm.

[0027] C is a quantitative graph of the germinal vesicle breakdown (GVBD) rate of oocytes in young (n=3), old+PBS (n=5), and old+Sal (n=5) mice 4 hours after IVM;

[0028] D is a representative image of oocyte maturation in young (n=3), old + PBS (n=5), and old + Sal (n=5) mice after IVM, scale bar: 160 μm;

[0029] E is a quantification of the polar body (PB) extrusion rate of mature oocytes from young (n=3), old+PBS (n=5) and old+Sal (n=5) mice after IVM, ns: p>0.05; *: p<0.05; **: p<0.01; ***: p<0.001, the results represent the mean ± SEM from at least 3 independent experiments, and statistical analysis was performed using a two-tailed unpaired t-test.

[0030] Figure 4Salidroside can restore mitochondrial autophagy in aged mouse oocytes; A is the result of mitochondrial autophagy-related protein detection; B and C are the statistical results of co-staining of mitochondria and lysosomes of oocytes and Pearson correlation coefficient, the upper scale is 80μm, and the lower scale is 20μm; D and E are mitochondrial autophagy tracer staining and fluorescence statistics, the upper scale is 80μm, and the lower scale is 20μm, n***: p<0.001. The results represent the mean ± SEM of at least 3 independent experiments, and the two-tailed unpaired t test was used for statistical analysis. DETAILED DESCRIPTION

[0031] The present invention provides the use of salidroside in improving the quality of oocytes, fertilization and embryonic development after fertilization of advanced females. In order to make the purpose, technical scheme and effect of the present invention clearer and more specific, the present invention is further described in detail below. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0032] Salidroside (also known as Salidroside in Chinese, Salidroside in English, abbreviated as Sal, structural formula see Figure 1 ) is one of the main active ingredients in the root of Rhodiola rosea, and is a traditional Chinese medicine with low toxicity and few side effects. Salidroside is considered to be an effective drug for preventing and treating altitude sickness. Based on the original efficacy of salidroside, the present invention has found through animal experiments that salidroside can improve the quality of oocytes, fertilization and embryonic development after fertilization of elderly females, and has a certain effect in delaying ovarian aging.

[0033] Specifically, the embodiments of the present invention provide the use of salidroside in the preparation of a drug for improving the quality of oocytes, fertilization and embryonic development after fertilization in older females.

[0034] Furthermore, the salidroside improves the quality of oocytes by enhancing mitochondrial autophagy in oocytes of advanced-age females.

[0035] The medicine containing an effective amount of salidroside in the embodiment of the present invention has the following technical advantages:

[0036] 1) The drug is over-the-counter and easily available;

[0037] 2) The drug itself has been proven effective through years of clinical trials, and can effectively improve the body's altitude sickness when taken in a high altitude environment;

[0038] 3) Using C57 mice as experimental subjects, it was demonstrated that appropriate concentrations of salidrosides for treating aged mice could protect the ovarian function of aged mice and delay reproductive aging in aged mice.

[0039] Furthermore, the elderly female is a woman over 30 years old, preferably a woman over 35 years old.

[0040] Furthermore, the drug comprises salidroside at a concentration of 75 mg / kg (kg is the unit of body weight of the user).

[0041] The embodiment of the present invention provides a drug for improving the quality of oocytes, fertilization and embryonic development after fertilization of advanced-age females, wherein the drug comprises an effective amount of salidroside.

[0042] The specific details about the drugs are mentioned above and will not be repeated here.

[0043] The embodiment of the present invention provides the use of salidroside in the preparation of a drug for improving in vitro maturation of oocytes of advanced females.

[0044] The salidroside is added to the in vitro maturation culture medium of oocytes of advanced-age females to increase the germinal vesicle rupture rate and polar body extrusion rate of oocytes, so as to improve the in vitro maturation of oocytes of advanced-age females.

[0045] Furthermore, the drug includes salidroside at a concentration of 25 μM.

[0046] The present invention is described in detail below through specific embodiments.

[0047] 10-month-old female mice (aged female mice) were intraperitoneally injected with 75 mg / kg salidroside (as the treatment group, also called salidroside-treated group) for 14 consecutive days, and 10-month-old female mice were intraperitoneally injected with an equal amount of PBS (as the control group) for 14 consecutive days. Meanwhile, young (2-month-old) female mice were intraperitoneally injected with an equal amount of PBS (as the control group) for 14 consecutive days; then, PMSG (pregnant mare serum gonadotropin) was injected on the 12th day, and HCG (human chorionic gonadotropin) was injected 48 hours later. Oocytes were collected 12-14 hours after the HCG injection (see Figure 2 Through superovulation, it was found that the number of normal MII oocytes in the treatment group was significantly higher than that in the control group (see Figure 2 B and C). This indicates that salidroside treatment can significantly improve the quality of normal MII stage oocytes.

[0048] In order to verify the developmental potential of oocytes after salidroside treatment, sperm from 12-week-old male mice were used for in vitro fertilization with normal MII-stage oocytes in the salidroside treatment group and normal MII-stage oocytes in the control group. The results showed that the fertilization rate of oocytes in the salidroside treatment group was significantly higher than that in the control group (see Figure 2 D and E) and blastocyst rate (see Figure 2 D and G) were significantly increased, but there was no significant difference in the 2-cell embryo rate (see Figure 2Middle F). This suggests a role for salidroside in improving oocyte fertilization and subsequent embryonic development.

[0049] In summary, the above data indicate that salidroside treatment is a measure that can improve the quality of oocytes in aged mice, increase the fertilization rate, and promote early embryonic development after fertilization.

[0050] To further study the regulatory mechanism of salidroside, 48 hours after PMSG injection, oocytes at the GV stage (germinal vesicle stage) of 10-month-old C57 mice were isolated and subjected to 14 hours of in vitro maturation (IVM) (see Figure 3 The young group was used as the positive control group, and the old group was used as the negative control group. 25uM salidroside was added to the experimental group during IVM. The oocyte morphology was then observed every hour. The germinal vesicle rupture (GVBD) of the oocytes was recorded (see Figure 3 B and C) and the first polar body ejection (PB) ( Figure 3 The results showed that salidroside treatment could significantly increase the oocyte GVBD rate at 2h, 3h, and 4h in aged mice. When observing the PB excretion rate, it was found that compared with the aged group without salidroside supplementation (see Figure 3 In the middle (C), salidroside treatment can significantly increase the polar body extrusion rate. This indicates that salidroside can promote the maturation of oocytes in aged mice.

[0051] Further studies have found that the expression of mitochondrial autophagy-related proteins (Bnip3, Pink1, Parkin, Lc3B) was upregulated after the injection of salidroside into GV-stage oocytes of aged mice (see Figure 4 Middle A), after the GV stage oocytes of aged mice were treated with salidroside in vitro, the Pearson correlation coefficient of the fluorescence signal of mitochondria and lysosomes was significantly upregulated (see Figure 4 B and C); the fluorescence level of the mitochondrial autophagy tracer was also significantly upregulated (see Figure 4 D and E). This suggests that salidroside can improve the quality of oocytes by rescuing mitochondrial autophagy in oocytes of aged mice.

[0052] Therefore, the present invention provides a new treatment scenario of salidroside: appropriate dose of salidroside treatment can promote the maturation, fertilization and subsequent embryonic development potential of ovarian aging oocytes.

[0053] It should be understood that the application of the present invention is not limited to the above examples. For ordinary technicians in this field, improvements or changes can be made based on the above description. All these improvements and changes should fall within the scope of protection of the claims attached to the present invention.

Claims

1. The application of salidroside in the preparation of drugs for improving the quality of oocytes, fertilization and embryonic development after fertilization in elderly females.

2. The use according to claim 1, characterized in that: The salidroside improves the quality of oocytes by enhancing mitochondrial autophagy in oocytes of advanced-age females.

3. The use according to claim 1, characterized in that: Improving the fertilization and post-fertilization embryonic development of oocytes of advanced-age females includes increasing the fertilization rate, 2-cell rate and embryo rate of oocytes of advanced-age females after in vitro fertilization.

4. The use according to claim 1, characterized in that: The medicine comprises salidroside at a concentration of 75 mg / kg, wherein the 75 mg / kg means that the amount of salidroside required per kilogram of body weight of the user is 75 mg.

5. The use according to claim 1, characterized in that: The elderly females are women over 30 years old.

6. The use according to claim 5, characterized in that: The elderly females are women over 35 years old.

7. A drug for improving the quality of oocytes, fertilization and embryonic development after fertilization in advanced-age females, the drug comprising an effective amount of salidroside.

8. The drug according to claim 7, characterized in that The medicine comprises salidroside at a concentration of 75 mg / kg, wherein the 75 mg / kg means that the amount of salidroside required per kilogram of body weight of the user is 75 mg.

9. The use of salidroside in the preparation of drugs for improving in vitro maturation of oocytes in elderly females.

10. The use according to claim 9, characterized in that: The salidroside improves the in vitro maturation of oocytes of advanced-age females by increasing the germinal vesicle rupture rate and polar body expulsion rate of oocytes of advanced-age females; The drug included salidroside at a concentration of 25 μM.

Citation Information

Patent Citations

  • Application of salidroside in promoting growth and development of ovarian follicles and preparing ovulation promoting medicine

    CN116139157A

  • Culture medium for improving development of bovine in vitro fertilized embryos and cloned embryos

    US20200399587A1